The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some existing weight loss approaches, retatrutide appears to deliver a greater substantial decrease in body weight and enhance metabolic fu